El remdesivir para tratar la COVID-19: una revisión Cochrane

Ansems, Kelly; Grundeis, Felicitas; Dahms, Karolina; Mikolajewska, Agata; Thieme, Volker; Piechotta, Vanessa; Metzendorf, Maria-Inti; Stegemann, Miriam; Benstoem, Carina; Fichtner, Falk.
Emergencias (Sant Vicenç dels Horts) ; 35(6): 465-467, dic. 2023.
Artículo en Español | IBECS (España) | ID: ibc-227811

Documentos relacionados

  1. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2, Update Alert 3).
  2. Practical Remdesivir Synthesis through One-Pot Organocatalyzed Asymmetric (<i>S</i>)-P-Phosphoramidation.
  3. Remdesivir for Adults With COVID-19 : A Living Systematic Review for American College of Physicians Practice Points.
  4. Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects.
  5. Remdesivir (VEKLURY) for Treating COVID-19: Guinea Pig Ex Vivo and In Vivo Cardiac Electrophysiological Effects.
  6. Remdesivir Administration in COVID-19 Patients With Renal Impairment: A Systematic Review.
  7. When and which patients should receive remdesivir?
  8. Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase.
  9. Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.
  10. What is the role of remdesivir in patients with COVID-19?